Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer

Table 2 Feasibility: Treatment cycles delivered

	No. of patients	%
Cycles received
1	51	100
2	44	86.3
3	39	76.5
4	35	68.6
Percentage of intended dose delivered (per evaluable patient, ITT)1
Docetaxel		78.90
Cisplatin		78.70
Capecitabine		78.30
Percentage of intended dose delivered in patients receiving 4 courses (n = 34)
Docetaxel		92.90
Cisplatin		92.90
Capecitabine		91.60

¹ITT: Percentage of dose delivered of all four courses divided by the amount of patients who could have received the full course.